These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20978369)

  • 21. [Adalimumab in Crohn's disease - data from real life].
    López San Román A; Van Domselaar M; Garrido E
    Rev Esp Enferm Dig; 2008 Nov; 100(11):671-5. PubMed ID: 19159169
    [No Abstract]   [Full Text] [Related]  

  • 22. [Humanization of Murine Monoclonal anti-hTNF Antibody: The F10 Story].
    Efimov GA; Raats JMH; Chirivi RGS; van Rosmalen JWG; Nedospasov SA
    Mol Biol (Mosk); 2017; 51(6):1062-1068. PubMed ID: 29271968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Crohn's disease--infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-alpha treatment].
    Schreiber S
    Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1770-4. PubMed ID: 17713889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis.
    Garcês S; Demengeot J; Benito-Garcia E
    Ann Rheum Dis; 2013 Dec; 72(12):1947-55. PubMed ID: 23223420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adalimumab in the therapy of uveitis in childhood.
    Mansour AM
    Br J Ophthalmol; 2007 Mar; 91(3):274-6. PubMed ID: 17322463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Commentary: infliximab or adalimumab in Crohn's disease?
    Sprakes MB; Hamlin PJ
    Aliment Pharmacol Ther; 2012 Aug; 36(4):398. PubMed ID: 22803644
    [No Abstract]   [Full Text] [Related]  

  • 27. [Patient information. Biological agents in inflammatory bowel disease].
    Van Domselaar M
    Rev Esp Enferm Dig; 2008 Dec; 100(12):798. PubMed ID: 19238770
    [No Abstract]   [Full Text] [Related]  

  • 28. Adalimumab, a novel anti-tumor necrosis factor-alpha antibody in a child with refractory Crohn's disease.
    Mian S; Baron H
    J Pediatr Gastroenterol Nutr; 2005 Sep; 41(3):357-9. PubMed ID: 16131995
    [No Abstract]   [Full Text] [Related]  

  • 29. Intestinal Behçet's disease: maintenance of remission with adalimumab monotherapy.
    Ariyachaipanich A; Berkelhammer C; Nicola H
    Inflamm Bowel Dis; 2009 Dec; 15(12):1769-71. PubMed ID: 19177427
    [No Abstract]   [Full Text] [Related]  

  • 30. Letter: infliximab and adalimumab in the management of Crohn's disease--are they really comparable?
    Lopez-Sanroman A; Gisbert JP
    Aliment Pharmacol Ther; 2012 Sep; 36(5):498-9. PubMed ID: 22860615
    [No Abstract]   [Full Text] [Related]  

  • 31. [1/2 The anti-TNF alpha drugs].
    Medjoub M; Limat S; Woronoff-Lemsi MC
    Soins; 2007 Oct; (719):59-61. PubMed ID: 18020248
    [No Abstract]   [Full Text] [Related]  

  • 32. Letter: are infliximab and adalimumab similar for Crohn's disease in clinical practice?
    Tursi A; Elisei W; Picchio M; Penna A
    Aliment Pharmacol Ther; 2013 Apr; 37(7):763-4. PubMed ID: 23458543
    [No Abstract]   [Full Text] [Related]  

  • 33. [Fully human anti TNF-alpha monoclonal antibodies (adalimumab, golimumab)].
    Hirohata S
    Nihon Rinsho; 2007 Jul; 65(7):1202-8. PubMed ID: 17642233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiologically significant joint improvement in a patient affected by psoriatic arthritis treated with adalimumab.
    Chimenti MS; Papoutsaki M; Teoli M; Zangrilli A; Perricone R; Chimenti S
    Clin Exp Rheumatol; 2009; 27(6):1056. PubMed ID: 20149332
    [No Abstract]   [Full Text] [Related]  

  • 35. Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab.
    Haennig A; Bonnet D; Thebault S; Alric L
    Gastroenterol Clin Biol; 2010 Sep; 34(8-9):e7-8. PubMed ID: 20189334
    [No Abstract]   [Full Text] [Related]  

  • 36. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.
    Lee TW; Fedorak RN
    Gastroenterol Clin North Am; 2010 Sep; 39(3):543-57. PubMed ID: 20951917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urticaria and angioedema in a patient with Behçet's disease treated with adalimumab.
    Sànchez-Cano D; Callejas-Rubio JL; Ortego-Centeno N; Ruiz-Villaverde R
    Clin Exp Rheumatol; 2006; 24(5 Suppl 42):S128. PubMed ID: 17067448
    [No Abstract]   [Full Text] [Related]  

  • 39. Adalimumab-induced psoriasis of the scalp with diffuse alopecia: a severe potentially irreversible cutaneous side effect of TNF-alpha blockers.
    El Shabrawi-Caelen L; La Placa M; Vincenzi C; Haidn T; Muellegger R; Tosti A
    Inflamm Bowel Dis; 2010 Feb; 16(2):182-3. PubMed ID: 19462433
    [No Abstract]   [Full Text] [Related]  

  • 40. Anti-tumor necrosis factor therapy for pediatric inflammatory bowel diseases.
    Bujanover Y; Weiss B
    Isr Med Assoc J; 2008; 10(8-9):634-9. PubMed ID: 18847168
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.